HT (conjugated equine oestrogen [CEO] with or without medroxyprogesterone acetate [MPA]) after menopause*
| Outcomes at 1 year | Trial | HT | Placebo | RRI (95% CI) | NNH (CI) |
|---|---|---|---|---|---|
| *HT = hormone therapy. Other abbreviations defined in glossary; RRI, NNH, and CI calculated from data in article. | |||||
| Incident stress urinary incontinence (UI) | CEO + MPA | 16% | 8.7% | 87% (61 to 118) | 14 (10 to 19) |
| CEO alone | 17% | 8.5% | 115% (77 to 162) | 11 (8 to 16) | |
| Incident urge UI | CEO + MPA | 11.4% | 10.8% | 15% (−1 to 34) | Not significant |
| CEO alone | 14% | 12% | 32% (10 to 58) | 27 (15 to 84) | |
| Relative risk (CI) | |||||
| Worsened amount of UI | CEO + MPA | 1.20 (1.06 to 1.36) | |||
| CEO alone | 1.59 (1.39 to 1.82) | ||||
| Worsened frequency of UI | CEO + MPA | 1.38 (1.28 to 1.49) | |||
| CEO alone | 1.47 (1.35 to 1.61) | ||||